Special items: Ovarian Cancer and Us blog best viewed in Firefox

Sunday, July 29, 2012

A phase I trial of dasatinib, a Src-family kinase Inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.

http://www.ncbi.nlm.nih.gov/m/pubmed/22837181/?i=3&from=ovarian%20cancer

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.